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Abstract In 2010, we reported the successful clinical
outcome related to a 20-month course of intravenous,
cyclical ceftriaxone, in a patient with adult-onset Alexander’s
disease. We now provide evidence that the progression of the
patient’s signs/symptoms was halted and reversed with a
4-year-long extension of the trial.
The patient’s clinical signs/symptoms were evaluated
before the start and every 6 months for 6 years. For the
early 2 years, without therapy, and for the following 4 years,
after intravenous ceftriaxone 2 g daily, for 3 weeks monthly
during the initial 4 months, then for 15 days monthly.
Gait ataxia and dysarthria were assessed clinically on a
0 to 4 scale. Palatal myoclonus and nystagmus/oscillopsia
were monitored by videotape and a self-evaluation scale.
The degree of disability, measured by a modified Rankin
scale, and the brain MRI were periodically evaluated.
Before ceftriaxone therapy, in a 2-year period, gait ataxia
and dysarthria worsened from mild to marked, palatal
myoclonus spread from the soft palate to lower facial
muscles, and the patient complained of oscillopsia. After 4
years of ceftriaxone therapy, gait ataxia and dysarthria
improved, from marked to mild at clinical rating scales. The
palatal myoclonus was undetectable; the patient did not
complained of oscillopsia and declared a progressively
better quality of life. Ceftriaxone was safe.
This case report providesClass IVevidence that intravenous
cycles of ceftriaxonemay halt and/or reverse the progression of
neurodegeneration in patients with adult-onset Alexander’s
disease and may significantly improve their quality of life.
Introduction
Alexander’s disease (AxD) is a rare, usually fatal, primary
disorder of astroglial cells in the central nervous system
(CNS) related to dominant mutations in the gene encoding
the type III intermediate filament protein, glial fibrillary
acidic protein (GFAP) (Brenner et al. 2001; Mignot et al.
2004; Li et al. 2005). The prevalent pathophysiological
hypothesis regarding AxD is based on the occurrence of a
toxic gain-of-function of mutated GFAP, which causes
intracytoplasmic aggregates in astrocytes (Rosenthal fibers),
containing GFAP, aB-Crystallin, the heat shock protein 27,
and ubiquitin (Mignot et al. 2004; Li et al. 2005), and on the
occurrence of excitotoxicity related to impairment of the
buffering capacity of dystrophic astrocytes and of their
ability to metabolize extracellular glutamate (Mignot et al.
2004; Tian et al. 2010). Therefore, in AxD, lowering the
production of GFAP and promoting its degradation and/or
the enhancement of the astroglial glutamate uptake from the
extracellular fluid may have potential therapeutic effects. No
treatment is at present available for this neurodegenerative
disorder, although recent data, in vitro and in animal models
JIMD Reports
DOI 10.1007/8904_2012_180
Communicated by: Ertan Mayatepek
Competing interests: None declared
Electronic supplementary material: The online version of this
article (doi:10.1007/8904_2012_180) contains supplementary
material, which is available to authorized users.
G.P. Sechi (*) :G.A. Deiana : E. Sechi
Department Clinical and Experimental Medicine, University of
Sassari, Viale S. Pietro 10, 07100 Sassari, Italy
e-mail: gpsechi@uniss.it
I. Ceccherini : T. Bachetti
Institute “Giannina Gaslini”, Laboratory of Molecular Genetics,
Genova, Italy
P. Balbi
Laboratory of Clinical Neurophysiology, Scientific Institute of
Milan IRCCS, ‘Salvatore Maugeri’ Foundation, Milano, Italy
of AxD, indicate that drugs such as the b-lactam antibiotic
ceftriaxone and the tricyclic antidepressant clomipramine
may have potential therapeutic effects (Bachetti et al. 2010;
Cho et al. 2010). In particular, clomipramine lowers the
production of GFAP in an animal model of AxD and delays
the appearance of aggregates in astrocytes from the animal
model (Cho et al. 2010). Ceftriaxone enhances the degrada-
tion of GFAP aggregates in a cellular model of AxD
(Bachetti et al. 2010), and may also counteract neuro-
degeneration due to glutamatergic excitotoxicity, based
on its ability to increase glutamate transporter subtype
1 (GLT-1) activity in astrocytes (Rothstein et al. 2005).
Previously, we reported the successful clinical outcome
related to a 20-month course of intravenous, cyclical
ceftriaxone in a patient with an adult form of AxD and a
rapidly progressive clinical course (Sechi et al. 2010a). Here
we studied the tolerability and therapeutic effects of cycles
of ceftriaxone in this patient at a 4-year follow-up.
Methods
The patient is a 44-year-old woman carrying the p.R70Q
and p.D157N GFAP mutations with adult-onset AxD
(Sechi et al. 2010a). The prominent clinical signs/symptoms
were dysarthria, gait ataxia, and palatal myoclonus from the
age of 38 years and evoked nystagmus/oscillopsia from
the age of 40 years. We previously reported the effect of a
20-month long trial of ceftriaxone therapy. At that time, the
patient declared an improvement of her clinical status,
which was in agreement with clinical (ataxia, dysarthria)
and electrophysiological (nystagmography recording) data
(Sechi et al. 2010a). We presently report an extension of the
trial encompassing a 6-year-long observation.
Gait ataxia, dysarthria, palatal myoclonus, and evoked
nystagmus/oscillopsia were evaluated every 6 months over
a 6-year period. For the first 2 years, without therapy, and
for the following 4 years, after intravenous ceftriaxone 2 g
daily, for 3 weeks monthly during the initial 4 months, then
for 15 days monthly. Among the ceftriaxone cycles, a
probiotic preparation was administered by mouth once
daily: FlorVis-gg, containing 6 milliards of Lactobacillus
rhamnosus. The patient’s body weight was 60 kg. Her
Mini-Mental State Examination score was 30. Intravenous
ceftriaxone was administered by a chronic subcutaneously
implanted port on the chest.
Gait ataxia and dysarthria were assessed clinically on a
0 to 4 scale (0 ¼ no disturbance, 1 ¼ mild, 2 ¼ moderate,
3 ¼ marked, 4 ¼ severe). In particular, speech was
assessed during normal conversation for at least 10 min,
and the severity of dysarthria evaluated according to the
following rating scale:
– 0: no disturbance.
– 1: mild. The speech is impaired, but all the words are
understandable.
– 2: moderate. Occasional words difficult to understand.
– 3: marked. Many words difficult to understand.
– 4: severe. Only single words are understandable.
For evaluating gait ataxia, instead, the patient was asked
to walk at a safe distance parallel to a wall, including a turn
around to face the opposite direction of gait (half-turn), and
to walk in tandem without support. The severity of gait
ataxia was rated as follows:
– 0: no disturbance.
– 1: mild. Slight difficulties, only evident when walking
in tandem.
– 2: moderate. Definite staggering, difficulties in half-
turn but without support.
– 3: marked. Marked staggering, intermittent support of
the wall required.
– 4: severe. Walking is only possible with strong support,
stroller, or accompanying person.
Palatal myoclonus was monitored by videotape and the
progressive involvement of contiguous muscles noticed.
Videotape examinations were conducted in the same physical
environment and conditions and with the same video
equipment. Oscillopsia was monitored by a self-evaluation
scale (severe, moderate, mild, no oscillopsia). The degree of
disability was measured, every year, for 6 years, by a
modified Rankin scale (van Swieten et al. 1988). The scale
runs from 0–6, running from perfect health without symp-
toms to death. Brain MRI was evaluated about every 2 years.
Periodic controls of hematological parameters, electrocardi-
ography (ECG) and electroencephalography (EEG) were
performed. The patient gave written informed consent. The
study was approved by the local ethics committee.
Results
Before ceftriaxone therapy, during the first 2 years of
observation, the patient’s gait ataxia and the dysarthria
worsened progressively, from mild to marked at clinical
rating scales, and the palatal myoclonus spread, after about
10 months, from the soft palate to lingual and lower facial
muscles. At the beginning of the study, eye movement
recording (EMR) was normal and the patient did not
complain of oscillopsia. After about 16 months, at EMR,
bilateral hypometric horizontal saccades and horizontal left
gaze evoked nystagmus with waveform-type pendular-like
mixed were present, and the patient complained of severe
oscillopsia. After 2 years without therapy, the gait ataxia,
the oscillopsia, and the dysarthria prevented a completely
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independent way of life (Rankin score, 3). Brain MRI
revealed bilateral, high signal-intensity areas posteriorly in
the periventricular white matter, pyramidal tracts of the
medulla, and cerebellar white matter (Sechi et al. 2010a).
After about 2 years of ceftriaxone therapy, the severity of
palatal myoclonus did not worsen; the gait ataxia and the
dysarthria improved from marked to moderate at clinical
rating scales. The evoked nystagmus showed a reduced
amplitude in comparison with the previous recordings, with
improvement in the ability to read or watch television. The
patient rated her oscillopsia as mild. The patient rated
herself as improved and declared a better quality of life
(Rankin score, 1–2) (Sechi et al. 2010a).
After about 4 years of ceftriaxone therapy, the gait ataxia
and the dysarthria showed a definite improvement from
marked to mild at clinical rating scales. The palatal
myoclonus, after about 3 years, disappeared from lower
facial muscles and tongue, and after about 4 years it was
undetectable (videos 1, 2). The patient did not complain of
oscillopsia, rated herself as definitively improved, and
declared a progressively better quality of life (Rankin score, 1)
(Fig. 1). Importantly, different examiners blinded to the
treatment, at the different time points, agreed for a
progressive improvement of the gait ataxia, dysarthria,
and palatal myoclonus in the patient. On follow-up
examination, the signal-intensity changes on brain MRI
did not reverse but did not progress further or show atrophy
in involved areas (Fig. 2a–d). Ceftriaxone did not have
obvious, major toxicity in the patient. After 7 months of
therapy, the patient had a mycotic vaginal infection treated
with miconazole. After 3.5 years, mainly during ceftriaxone
cycles, the patient occasionally complained of single, right
or left myoclonic jerks in upper limbs, about seven times a
week. EEG showed a normal background rhythm without
epileptiform activity. The patient refused any therapy for
myoclonic jerks. Periodic controls, of white and red blood
cell counts, glucose, creatinine, serum electrolytes, liver
function tests, ECG, and EEG were normal.
Discussion
The available literature data indicate that in patients with
adult-onset AxD, the clinical course is usually that of a
progressive neurodegenerative disease without spontaneous
remission (Schwankhaus et al. 1995; Balbi et al. 2010), as
also shown by the evaluation of our patient during the first
2 years of observation without therapy. Thus, it seems very
unlikely that the progressive improvement of the patient
over a 4-year period, after ceftriaxone therapy, may be due
to the natural course of the disease.
This case report provides Class IVevidence that parenteral
cycles of ceftriaxone were able to halt and reverse the
progression of the disease and to improve significantly the
quality of life in a patient with adult-onset AxD and a rapidly
progressive clinical course. Importantly, a definite improve-
ment was achieved slowly for all the signs evaluated, from
few months to 3 years, with a different timescale which
seems related to the time necessary to the development and
progression of the different signs, as exemplified from palatal
myoclonus. On follow-up examination, brain MRI changes
did not progress further, or show atrophy in involved areas.
Because the available literature indicates that in patients with
AxD the brain MRI signal intensities are not static but may
vary in time and progress to atrophy in involved areas
(Sawaishi 2009), this finding also may be indicative of a
therapeutic effect of ceftriaxone in our patient with AxD. At
the used dosages, cyclical administration of ceftriaxone was
safe. Some adverse effects, as the self-limiting myoclonic
jerks, indicate that ceftriaxone may lower the epileptogenic
threshold. This adverse event needs long-term supervision,
and an eventual lowering of ceftriaxone dosages, mainly in
the infantile form of AxD, which is frequently characterized
by the occurrence of epileptic seizures (Li et al. 2005).
Recent, essential advances in the understanding of the
pathophysiology of AxD indicate that a dynamic and
reversible aggregation of mutated GFAP may occur
(Mignot et al. 2004; Mignot et al. 2007), and that in this
pathology at least three main biochemical mechanisms play
a fundamental role in promoting neurodegeneration:
(1) The key initiating event is the expression and accumu-
lation in astrocytes of mutant GFAP above a toxic
threshold, with consequent, progressive astroglial damage
(Messing et al. 1998). (2) The decrease of the cytoplasmic
content of the small heat-shock proteins (sHPSs) HSP27
and aB-Crystallin in astrocytes, due to their sequestration in
GFAP aggregates (Mignot et al. 2004; Der Perng et al.
2006). Indeed, it has been shown that overexpression of
these sHPSs in astrocytes promotes dissolution of GFAP
aggregates (Tang et al. 2010). (3) The impairment of the
buffering capacity of dystrophic astrocytes and of their
ability to metabolize extracellular glutamate, with chronic

























Fig. 1 Evolution of the degree of disability over time: 0–2 years,
before treatment; 2–6 years, after ceftriaxone treatment
JIMD Reports 69
excitotoxicity, may play an important role in the pathogen-
esis of secondary oligodendrocyte and neuronal degenera-
tion in AxD (Tian et al. 2010; Sechi et al. 2010b). Given
these findings, it is conceivable that in AxD, for achieving
an effective and long-term suppression of neurodegenera-
tion, a chemical agent, or a combination of chemical agents
that inhibit multiple biochemical injurious mechanisms in
astrocytes may be needed. In such a scenario, ceftriaxone
may be of particular interest. This b-lactam antibiotic is a
safe and multipotent agent used for decades as antimicro-
bial (Nau et al. 1993). In 2005, ceftriaxone was suggested
as a potential therapeutic agent in neurodegenerative
diseases comprising glutamate-mediated toxicity, based on
its ability to increase glutamate transporter subtype 1 (GLT-1)
activity in astrocytes that are genetically impaired in their
GLT-1 expression (Rothstein et al. 2005). In 2010, we
showed that ceftriaxone is also able to successfully
eliminate the toxic effects of misfolded GFAP in a cellular
model of AxD by decreasing GFAP intracytoplasmic
aggregates (Bachetti et al. 2010). Underlying mechanisms
include mutant GFAP elimination, concurrent with
upregulation of HSP27 and aB-Crystallin, polyubiquitina-
tion, enhancement of autophagy, and GFAP promoter
downregulation (Bachetti et al. 2010). Interestingly, a recent
study in an animal axotomy model showed that ceftriaxone
was able to suppress, after 28 days of parenteral adminis-
tration, the reactive increase of astroglial GFAP expression
to control level, at 200 mg/kg, daily dose (Yamada and
Jinno 2011). Another, very recent study in a mouse model
of AxD documented that overexpression of the transcrip-
tion factor Nrf2 (nuclear factor erythroid 2-related factor 2)
dramatically reduced astrocytic GFAP content in all brain
regions examined and restored body weights in R236H
mice to near wild-type levels (Lapash Daniels et al. 2012).
Since the astrocytic induction of Nrf2 is involved in the
neuroprotective action of ceftriaxone (Lewerenz et al.
2009), this mechanism also may partly explain the
therapeutic effect of this drug in AxD. Notably, in AxD
the ceftriaxone activation of cellular mechanisms involved
in the disposal of mutant GFAP acts in a synergistic way
with its ability to counteract the chronic glutamatergic
excitotoxicity in this pathology, with consequent rescue of
the secondary oligodendrocytes and neuronal degeneration
related to excitotoxicity (Sechi et al. 2010b).
Because AxD is rare and its presentation and course
vary, evaluation of treatments in placebo-controlled trials is
Fig. 2 a–d: Axial T2-WMR images, at the beginning of ceftriaxone
therapy (a, b) and after about 4 years of ceftriaxone therapy (c, d).
Bilateral high signal-intensity areas are seen posteriorly in the
periventricular white matter (arrows) (a, c); MR scan obtained at a
lower level shows involvement of the descending pyramidal tracts of
the medulla (arrowheads) and deep cerebellar white matter (arrows)
(b, d). On follow-up examination, the signal-intensity changes did not
reverse but did not progress further, or show atrophy in involved areas
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very difficult (Sechi et al. 2010a). Instead, prolonged,
longitudinal single patient studies may be a useful approach
to identify new therapeutic strategies in this disorder (Sechi
et al. 2010a). The successful clinical outcome related to
ceftriaxone documented in our patient highlights the
possibility that this safe drug may be useful for other
AxD patients and puts the relevant question whether
ceftriaxone may also be useful in treating other diseases
caused by intracellular accumulation and aggregation of
misfolded proteins (Sechi et al. 2011), particularly other
neurodegenerative diseases with astrocyte involvement.
Synopsis
Long-term intravenous cycles of ceftriaxone have a
therapeutic role in adult-onset Alexander’s disease with a
rapidly progressive clinical course.
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